Impact of time‐of‐day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study

Hepatology Research, Journal Year: 2025, Volume and Issue: 55(5), P. 741 - 751

Published: Feb. 9, 2025

Abstract Aim This study aimed to evaluate the impact of infusion timing time‐of‐day on clinical outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated atezolizumab plus bevacizumab combination therapy. Methods A retrospective analysis was conducted using data from 751 HCC between September 2020 and April 2024. Patients were categorized into morning (AM; n = 351) afternoon (PM; 400) groups based time‐of‐day. Outcomes, including progression‐free survival (PFS), overall survival, objective response rate, disease control assessed Kaplan–Meier Cox regression analysis. Results The PFS significantly longer AM group (8.6 months, 95% CI 7.6–10.5) compared PM (6.0 5.4–7.0; p 0.006). In contrast, similar (AM: 24.7 months vs. PM: 21.4 months; 0.99). revealed that an independent favorable predictor (HR 1.23, 1.04–1.45). Additionally, demonstrated superior rate group, suggesting better tumor control. Conclusion Morning is associated improved rates patients, highlighting potential for optimizing treatment through circadian timing.

Language: Английский

Mitochondrial Gene Scoring System: Predicting Prognosis and Precision Therapy for TACE Non-Response in Hepatocellular Carcinoma Patients

Journal of Cancer, Journal Year: 2024, Volume and Issue: 16(2), P. 629 - 647

Published: Dec. 31, 2024

Given the crucial role of mitochondria in prognosis and treatment hepatocellular carcinoma (HCC), we aim to develop two independent mitochondrial scoring systems separately predict patient likelihood transarterial chemoembolization non-response (TACE NR).

Language: Английский